Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Fedratinib (hydrochloride hydrate)

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].

Product Specifications

CAS Number

1374744-69-0

Product Name Alternative

TG-101348 (hydrochloride hydrate) ; SAR 302503 (hydrochloride hydrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; JAK

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fedratinib-hydrochloride-hydrate.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

[H]Cl.[H]O[H].[H]Cl.O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O

Molecular Formula

C27H40Cl2N6O4S

Molecular Weight

615.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13 (4) :311-20.|[2]Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13 (4) :321-30.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

JAK2

Citation 01

J Pharm Sci. 2025 Feb;114 (2) :1444-1454.|Am J Clin Nutr. 2020 Jan 1;111 (1) :110-121.|Biomed Pharmacother. 2024 May:174:116447.|bioRxiv. 2024 May 6:2023.06.07.544058.|bioRxiv. 2024 Nov 5:2024.02.02.578646.|bioRxiv. 2024 September 24.|bioRxiv. 2025 February 21.|bioRxiv. 2025 Nov 26.|BMC Cancer. 2022 Aug 13;22 (1) :885.|Cancer Biol Ther. 2024 Dec 31;25 (1) :2432117.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Cell Prolif. 2020 Feb;53 (2) :e12742.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2024 Apr 25;187 (9) :2288-2304.e27.|EMBO Rep. 2019 Jun;20 (6) :e47202.|Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2023 Oct 19;125 (Pt A) :111087.|Int J Mol Sci. 2023 May 25;24 (11) :9243.|Invest Ophthalmol Vis Sci. 2024 Sep 3;65 (11) :21.|IUBMB Life. 2018 Jan;70 (1) :81-91.|J Exp Clin Cancer Res. 2025 Jan 2;44 (1) :2.|J Med Chem. 2021 Feb 25;64 (4) :2228-2241.|J Neuroinflammation. 2022 Oct 10;19 (1) :253.|J Pharm Sci. 2025 Feb;114 (2) :1444-1454.|Life Sci. 2023 May 15:321:121608.|Mol Cancer. 2021 May 29;20 (1) :80.|Mol Cancer. 2023 May 20;22 (1) :86.|Mol Cell Biochem. 2025 Apr;480 (4) :2645-2660.|Mol Pharm. 2017 Jan 3;14 (1) :274-283. |Mol Pharmacol. 2022 Jun;101 (6) :381-389.|Mol Ther Nucleic Acids. 2020 Sep 4;21:900-915. |Mol Ther Oncol. 2024 Jun 07.|Molecules. 2018 Aug 18;23 (8) . pii: E2071.|Nat Commun. 2025 Sep 29;16 (1) :8560.|Nature. 2023 Jun;618 (7963) :151-158.|Neuropsychiatr Dis Treat. 2020 Apr 1;16:891-900.|Patent. US20210128545A1.|Research Square Preprint. 2020 Jun.|Sci Rep. 2025 Jan 24;15 (1) :3124.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2020 Dec 26;5 (1) :295.|Signal Transduct Target Ther. 2022 Feb 23;7 (1) :52.|SSRN. 2025 Jul 4.|Toxicol Appl Pharmacol. 2024 Dec 24:495:117216.|University of California. Pharmaceutical Sciences and Pharmacogenomics. 2021 Apr.|University of Michigan. 2023 Sep.|University of Michigan. 2024.|University of Pennsylvania. 2025.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

CD8 (RIV11), CF594 conjugate, 0.1mg/mL
BNC940333-500 1x 500 µL

CD8 (RIV11), CF594 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD11a (Cris-3), CF647 conjugate, 0.1mg/mL
BNC470151-500 1x 500 µL

CD11a (Cris-3), CF647 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
Fibronectin (HFN7.1), CF640R conjugate, 0.1mg/mL
BNC400270-100 1x 100 µL

Fibronectin (HFN7.1), CF640R conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD3e (B-B12), CF488A conjugate, 0.1mg/mL
BNC881052-500 1x 500 µL

CD3e (B-B12), CF488A conjugate, 0.1mg/mL

Sign In for Pricing
View Details
Complement C4d (C4D204), CF568 conjugate, 0.1mg/mL
BNC680204-100 1x 100 µL

Complement C4d (C4D204), CF568 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
P53 (PAb122), CF740 conjugate, 0.1mg/mL
BNC740338-100 1x 100 µL

P53 (PAb122), CF740 conjugate, 0.1mg/mL

Sign In for Pricing
View Details